|
1
|
Manuali E, De Giuseppe A, Feliziani F, et
al: CA 15-3 cell lines and tissue expression in canine mammary
cancer and the correlation between serum levels and tumour
histological grade. BMC Vet Res. 8:862012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schneider R: Comparison of age, sex, and
incidence rates in human and canine breast cancer. Cancer.
26:419–426. 1970. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mottolese M, Morelli L, Agrimi U, et al:
Spontaneous canine mammary tumors. A model for monoclonal antibody
diagnosis and treatment of human breast cancer. Lab Invest.
71:182–187. 1994.PubMed/NCBI
|
|
4
|
Phillips JC, Lembcke L and Chamberlin T: A
novel locus for canine osteosarcoma (OSA1) maps to CFA34, the
canine orthologue of human 3q26. Genomics. 96:220–227. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
MacEwen EG: Spontaneous tumors in dogs and
cats: models for the study of cancer biology and treatment. Cancer
Metastasis Rev. 9:125–136. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Peleteiro M: Tumores mamários na cadela e
na gata. Revista Portuguesa de Ciências Veterinárias. 89:10–29.
1994.
|
|
7
|
Andrade FH, Figueiroa FC, Bersano PR,
Bissacot DZ and Rocha NS: Malignant mammary tumor in female dogs:
environmental contaminants. Diagn Pathol. 5:452010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hamilton A and Hortobagyi G: Chemotherapy:
what progress in the last 5 years? J Clin Oncol. 23:1760–1775.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Winer E, Gralow J, Diller L, et al:
Clinical cancer advances 2008: major research advances in cancer
treatment, prevention, and screening - a report from the American
Society of Clinical Oncology. J Clin Oncol. 27:812–826. 2009.
View Article : Google Scholar :
|
|
10
|
Hsiao YH, Chou MC, Fowler C, Mason JT and
Man YG: Breast cancer heterogeneity: mechanisms, proofs, and
implications. J Cancer. 1:6–13. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yuan L, Collins AR, Dai J, Dubocovich ML
and Hill SM: MT(1) melatonin receptor overexpression enhances the
growth suppressive effect of melatonin in human breast cancer
cells. Mol Cell Endocrinol. 192:147–156. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Maganhin CC1, Carbonel AA, Hatty JH, et
al: Melatonin effects on the female genital system: a brief review.
Rev Assoc Med Bras. 54:267–271. 2008.(In Portuguese). View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Luchetti F, Canonico B, Betti M, et al:
Melatonin signaling and cell protection function. FASEB J.
24:3603–3624. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cos S and Sánchez-Barceló EJ: Melatonin,
experimental basis for a possible application in breast cancer
prevention and treatment. Histol Histopathol. 15:637–647.
2000.PubMed/NCBI
|
|
15
|
Neto J and Scaldaferri P: Melatonina e
câncer - revisão da literatura. Revista Brasileira Cancerol.
51:49–58. 2005.(In Portuguese).
|
|
16
|
Jablonska K, Pula B, Zemla A, et al:
Expression of melatonin receptor MT1 in cells of human invasive
ductal breast carcinoma. J Pineal Res. 54:334–345. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mediavilla MD, Sanchez-Barcelo EJ, Tan DX,
Manchester L and Reiter RJ: Basic mechanisms involved in the
anti-cancer effects of melatonin. Curr Med Chem. 17:4462–4481.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sturgeon SR, Doherty A, Reeves KW, et al:
Urinary levels of melatonin and risk of postmenopausal breast
cancer: Women’s health initiative observational cohort. Cancer
Epidemiol Biomarkers Prev. 23:629–637. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sanchez-Barcelo EJ, Mediavilla MD,
Alonso-Gonzalez C and Rueda N: Breast cancer therapy based on
melatonin. Recent Pat Endocr Metab Immune Drug Discov. 6:108–116.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bejarano I, Espino J, Barriga C, Reiter
RJ, Pariente JA and Rodríguez AB: Pro-oxidant effect of melatonin
in tumour leucocytes: relation with its cytotoxic and pro-apoptotic
effects. Basic Clin Pharmacol Toxicol. 108:14–20. 2011. View Article : Google Scholar
|
|
21
|
Rodriguez C, Martín V, Herrera F, et al:
Mechanisms involved in the pro-apoptotic effect of melatonin in
cancer cells. Int J Mol Sci. 14:6597–6613. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cucina A, Proietti S, D’Anselmi F, et al:
Evidence for a biphasic apoptotic pathway induced by melatonin in
MCF-7 breast cancer cells. J Pineal Res. 46:172–180. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Eck KM, Yuan L, Duffy L, et al: A
sequential treatment regimen with melatonin and all-trans retinoic
acid induces apoptosis in MCF-7 tumour cells. Br J Cancer.
77:2129–2137. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Blask DE, Sauer LA and Dauchy RT:
Melatonin as a chronobiotic/anticancer agent: cellular,
biochemical, and molecular mechanisms of action and their
implications for circadian-based cancer therapy. Curr Top Med Chem.
2:113–132. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hardeland R, Pandi-Perumal SR and
Cardinali DP: Melatonin. Int J Biochem Cell Biol. 38:313–316. 2006.
View Article : Google Scholar
|
|
26
|
Lai L, Yuan L, Cheng Q, Dong C, Mao L and
Hill SM: Alteration of the MT1 melatonin receptor gene and its
expression in primary human breast tumors and breast cancer cell
lines. Breast Cancer Res Treat. 118:293–305. 2009. View Article : Google Scholar
|
|
27
|
Grant SG, Melan MA, Latimer JJ and
Witt-Enderby PA: Melatonin and breast cancer: cellular mechanisms,
clinical studies and future perspectives. Expert Rev Mol Med.
11:e52009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Misdorp W, Else R, Hellmen E and Lipscomb
E: Definitions and explanatory notes. Who Histological
Classification of Mammary Tumors of the Dog and Cat. Armed Forces
Institute of Pathology; Washington: pp. 18–27. 1999
|
|
29
|
Cassali G, Bertagnolli A, Lavalle G, et
al: Perpectives for diagnosis, prognosis and treatment of mammary
neoplasms in dogs. In: 34th World Small Animal Veterinary Congress
- WSAVA; São Paulo. 2009
|
|
30
|
Li XR, Liu M, Zhang YJ, et al: ER, PgR,
HER-2, Ki-67, topoisomerase IIα, and nm23-H1 proteins expression as
predictors of pathological complete response to neoadjuvant
chemotherapy for locally advanced breast cancer. Med Oncol.
28(Suppl 1): S48–S54. 2011. View Article : Google Scholar
|
|
31
|
Livak K and Schimittgen T: Analyzing
real-time PCR data by the comparative C(T) method. Nature
Protocols. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jung JW, Park SB, Lee SJ, Seo MS, Trosko
JE and Kang KS: Metformin represses self-renewal of the human
breast carcinoma stem cells via inhibition of estrogen
receptor-mediated OCT4 expression. PLoS One. 6:e280682011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rato AG, Pedrero JG, Martinez MA, del Rio
B, Lazo PS and Ramos S: Melatonin blocks the activation of estrogen
receptor for DNA binding. FASEB J. 13:857–868. 1999.PubMed/NCBI
|
|
34
|
Mao L, Cheng Q, Guardiola-Lemaître B, et
al: In vitro and in vivo antitumor activity of melatonin receptor
agonists. J Pineal Res. 49:210–221. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Leman ES, Sisken BF, Zimmer S and Anderson
KW: Studies of the interactions between melatonin and 2 Hz, 0.3 mT
PEMF on the proliferation and invasion of human breast cancer
cells. Bioelectromagnetics. 22:178–184. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sánchez-Hidalgo M, Guerrero JM, Villegas
I, Packham G and de la Lastra CA: Melatonin, a natural programmed
cell death inducer in cancer. Curr Med Chem. 19:3805–3821. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang J, Xiao X, Zhang Y, et al:
Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling
by melatonin to inhibit proliferation and induce apoptosis in
breast cancer cells. J Pineal Res. 53:77–90. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Oprea-Ilies G, Haus E, Sackett-Lundeen L,
et al: Expression of melatonin receptors in triple negative breast
cancer (TNBC) in African American and Caucasian women: relation to
survival. Breast Cancer Res Treat. 137:677–687. 2013. View Article : Google Scholar :
|
|
39
|
Collins A, Yuan L, Kiefer TL, Cheng Q, Lai
L and Hill SM: Overexpression of the MT1 melatonin receptor in
MCF-7 human breast cancer cells inhibits mammary tumor formation in
nude mice. Cancer Lett. 189:49–57. 2003. View Article : Google Scholar
|
|
40
|
Hill SM, Blask DE, Xiang S, et al:
Melatonin and associated signaling pathways that control normal
breast epithelium and breast cancer. J Mammary Gland Biol
Neoplasia. 16:235–245. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gonzalez-Angulo AM, Morales-Vasquez F and
Hortobagyi GN: Overview of resistance to systemic therapy in
patients with breast cancer. Adv Exp Med Biol. 608:1–22. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ram PT, Kiefer T, Silverman M, Song Y,
Brown GM and Hill SM: Estrogen receptor transactivation in MCF-7
breast cancer cells by melatonin and growth factors. Mol Cell
Endocrinol. 141:53–64. 1998. View Article : Google Scholar : PubMed/NCBI
|
